Browsing by Author Zalcberg, John

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 32  next >
Issue DateTitleAuthor(s)Citation
2005Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC)Beale, Philip; Clarke, Simon; Friedlander, Michael; Mitchell, Philip; White, Saxon; Zalcberg, John; Goldstein, David; Michael, M; Central Clinical School: Medicine; Western Clinical School: Westmead Millennium Institute; School of Public Health: NH&MRC Clinical Trials Centre; Medicine Faculty Office; Medicine; School of Public Health: NH&MRC Clinical Trials CentreAddition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC), Journal of Clinical Oncology, vol.23,(No 16S (June 1 Supplement)),2005,pp 3581-3581
2006Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.Beale, Philip; Clarke, Stephen; Friedlander, Michael; Goldstein, David; Michael, Michael; Mitchell, Paul L.; Thomson, Jacquelyn A.; White, Shane; Zalcberg, John; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteAddition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity., Clinical Colorectal Cancer, vol.6,(2),2006,pp 146-151
2016Advances in Molecular Pathology and Treatment of Periampullary CancersPrice, Timothy; Sjoquist, Katrin; Chandrasegaram, Manju D; Chen, John; Merrett, Neil D; Price, Timothy; Zalcberg, John; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreAdvances in Molecular Pathology and Treatment of Periampullary Cancers, Pancreas, vol.45, 1, 2016,pp 32-39
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Pavlakis, Nick; Simes, Robert John; Blondal, J; Burkes, R L; Gibbs, Peter; Jonker, D; Karapetis, Christos; Lee, U; Meharchand, J; Moore, Malcolm; O'Callaghan, Chris; Price, T.J.; Rubin, S; Shapiro, Jeremy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; Vickers, M; Zalcberg, John; Zhu, L; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreAssociation of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17, Annals of Oncology, vol.24, 4, 2013,pp 953-960
2010Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabSimes, Robert John; Arena, Sabrina; Bardelli, Alberto; Cutsem, E Van; De Roock, Wendy; Di Nicolantonio, Federica; Frattini, Milo; Jonker, Derek J.; Karapetis, Christos; Khambata-Ford, Shirin; Lamba, Simona; O'Callaghan, Chris; Piessevaux, Hubert; Sartore-Bianchi, Andrea; Siena, Salvatore; Tejpar, Sabine; Tu, D.; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials CentreAssociation of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab, JAMA: The Journal of the American Medical Association, vol.304, 16,pp 1812-1820
2005Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.Beale, Philip; Clarke, Stephen; Friedlander, Michael; Goldstein, David; Michael, Michael; Mitchell, P.; White, Shane; Zalcberg, John; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteAustralian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients., British Journal of Cancer, vol.92,(5),2005,pp 832-837
2007Cetuximab for the Treatment of Colorectal CancerSimes, Robert John; Zalcberg, John; Au, Heather Jane; Berry, Scott R.; et, al; Jonker, Derek J.; Karapetis, Christos (Chris); Krahn, Marianne; O’Callaghan, Chris J.; Price, Timothy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCetuximab for the Treatment of Colorectal Cancer, New England Journal of Medicine, vol.357,(20),2007,pp 2040-2048
2013Clinical Trials - Advancing National Cancer CareSjoquist, Katrin; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials CentreClinical Trials - Advancing National Cancer Care, Cancer Forum, vol.37, 1, 2013,pp 80-87
2015Clinical utility of ramucirumab in advanced gastric cancerChan, Matthew; Sjoquist, Katrin; Zalcberg, John; Northern Clinical School: Melanoma Institute of Australia; NH&MRC Clinical Trials CentreClinical utility of ramucirumab in advanced gastric cancer, Biologics (Print): targets & therapy, vol.9, N/A, 2015,pp 93-105
2014The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX studyCarter, Hannah; Howard, Kirsten; Schofield, Deborah; Simes, Robert John; Zannino, Diana; Price, Timothy; Tebbutt, Niall C; Zalcberg, John; Anaesthesia; School of Public Health: Public Health; Pharmacy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study, European Journal of Cancer, vol.50, 3, 2014,pp 535-543
2015Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinibGibbs, Emma; Lee, Chee Khoon; Lord, Sarah (Sally); Casali, Paolo G.; Cioffi, Angela; et al, Various; Goldstein, David; Joensuu, Heikki; Maki, Robert; Verweij, Jaap; Zalcberg, John; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreDevelopment and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib, European Journal of Cancer, vol.51, 7, 2015,pp 852-860
2002Efficacy, tolerability and management of raltitrexed (Tomudex TM) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trialsClarke, Stephen; Cunningham, David; Facchini, T.; Gonzalez Baron, M.; James, R.; Maroun, J.; Maughan, T. S.; Schulz, J.; Vincent, M.; Zalcberg, John; Concord Clinical School: ANZAC Research InstituteEfficacy, tolerability and management of raltitrexed (Tomudex TM) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials, European Journal Of Cancer, vol.38,(4),2002,pp 478-486
2009Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.Pavlakis, Nick; Au, Heather-Jane; et al, various; Jefford, Michael; Karapetis, Christos; Kennecke, Hagen; Koski, Sherryl; Moore, M J; O'Callaghan, Chris; Shapiro, Jeremy; Tu, Dongsheng; Zalcberg, John; Northern Clinical School: MedicineHealth-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial., Journal of Clinical Oncology, vol.27, 11,pp 1822-1828
2016The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04)Solomon, Michael; Ackland, Stephen; Burmeister, Bryan H.; Fisher, Richard; Goldstein, David; Leong, Trevor; Mackay, John; McClure, Bev; McKendrick, Joseph; McLachlan, Sue Anne; Ngan, S. Y.; Zalcberg, John; Central Clinical School: SurgeryThe impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04), European Journal of Cancer, vol.55, N/A, 2016,pp 15-26
2007Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising EfficacyBeale, Philip; Clarke, Stephen; Friedlander, Michael; Goldstein, David; Michael, Michael; Mitchell, Paul; White, Shane; Zalcberg, John; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteModification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy, Clinical Colorectal Cancer, vol.6,(8),2007,pp 578-582
2015Neuroendocrine tumours - Models for rare tumour managementChan, David; Goldstein, David; Zalcberg, John; Northern Clinical School: MedicineNeuroendocrine tumours - Models for rare tumour management, Cancer Forum, vol.39, 1, 2015,pp 13-16
2011Overview of controversies in oesophagogastric cancerCameron, Andrew; Sjoquist, Katrin; Zalcberg, John; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreOverview of controversies in oesophagogastric cancer, Cancer Forum, vol.35, 3, 2011,pp 139-141
2006Palifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy.Clarke, Stephen; Abdi, Ehtesham; Cesano, Alessandra; Chen, Mon-Gy; Davis, Ian D.; Gayko, Urte; Gutheil, John; Rosen, Lee S.; Schnell, Frederick M.; Zalcberg, John; Concord Clinical School: ANZAC Research InstitutePalifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy., Journal of Clinical Oncology, vol.24,(N/A),2006,pp 5194-5200
2002Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodiesClarke, Stephen; Millward, Michael; Ackland, Stephen P.; Garg, M. B.; Rischin, D.; Smith, J.; Toner, Guy C.; Zalcberg, John; Concord Clinical School: ANZAC Research Institute; MedicinePhase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies, Annals of Oncology, vol.13,(11),2002,pp 1810-1818
2013Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in PatientsWith Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 TrialSimes, Robert John; Zalcberg, John; Charpentier, Danielle; Couture, Felix; et al, Various; Jonker, Derek J.; Karapetis, Christos (Chris); Moore, Malcolm; Nott, Louise M; Price, Timothy; Shapiro, Jeremy; Siddiqui, Jehan; Siu, Lillian L; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentrePhase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in PatientsWith Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial, Journal of Clinical Oncology, vol.31, 19, 2013,pp 2477-2484